Kura Oncology Stock News

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11 th Annual SVB Leerink Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m. ET on Thursday, February 17, 2022.

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML).  The part

Kura Oncology (KURA) said the U.S. Food and Drug Administration ((FDA)) lifted the partial clinical hold on the KOMET-001 phase 1b study of KO-539 in patients with relapsed or

FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome KOMET-001 study to resume screening and enrollment of new patients Encouraging safety, tolerability and clinical activity observed among patients on study SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA ), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The partial clinical hold was lifted following agreement with the FDA on the Company''s mitigation strategy for differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML. "I am very proud of our team for working diligently with the FDA and site investigators to resolve the partial clinical hold in such a timely manner," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "Activities to resume patient screening are underway, and we look forward to expediting enrollment of patients in the Phase 1b study and determining the recommended Phase 2 dose for KO-539 in the coming months.

Kura Oncology (NASDAQ:KURA)s stock had its buy rating reiterated by equities research analysts at JMP Securities in a research note issued on Wednesday, TipRanks reports. They presently have a $26.00 target price on the stock. JMP Securities price objective points to a potential upside of 110.70% from the companys previous close. Other equities research analysts []

The stock price of Kura Oncology Inc (NASDAQ: KURA) increased by 4.75% in the most recent trading session. This is why it happened.

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma –

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus recommendation of Buy from the seven ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have []

Shares of Kura Oncology, Inc. (NASDAQ:KURA) gapped down before the market opened on Thursday . The stock had previously closed at $13.35, but opened at $12.75. Kura Oncology shares last traded at $13.57, with a volume of 1,825 shares trading hands. A number of research firms have recently issued reports on KURA. JMP Securities restated []